肿瘤标志物联合临床因素预测局部进展期直肠癌新辅助放化疗敏感性的价值  

Value of tumor markers combined with clinical factors in predicting the sensitivity of neoadjuvant chemoradiotherapy in locally advanced rectal cancer

作　　者：陶丹[1] 周菊英[1] 庄恒钊 王利利[2] TAO Dan;ZHOU Juying;ZHUANG Hengzhao(Department of Radiation Oncology,Dushu Lake Hospital Affiliated to Soochow University,Jiangsu,Suzhou 215000,China;不详)

机构地区：[1]苏州大学附属独墅湖医院肿瘤放疗科,江苏省苏州市215000 [2]苏州大学附属第一医院肿瘤放疗科

出　　处：《河北医药》2023年第6期869-871,875,共4页Hebei Medical Journal

基　　金：国家自然科学基金(编号:82073476)。

摘　　要：目的 探讨治疗前肿瘤标志物联合临床因素在预测直肠癌新辅助放化疗(nCRT)敏感性的价值。方法 收集了2013年8月至2020年12月行nCRT的97例直肠癌患者资料,纳入了性别、年龄、临床T/N分期、距肛缘距离、肿瘤最长径、肿瘤环周比、同步化疗方案、手术间隔时间,以及治疗前的血清CEA、CA199、CA125和CA724。依据肿瘤退缩反应程度进行分组。采用Pearson卡方检验比较组间的基线资料,再将P<0.05的变量纳入多因素模型进行Logistic回归分析。结果 多因素分析结果显示,治疗前CEA≤5 ng/ml和肿瘤最长径≤5 cm是患者出现肿瘤消退明显和pCR的独立预测因子(P<0.05)。结论 治疗前血清CEA和肿瘤大小对直肠癌新辅助放化疗敏感性的预测有重要价值。Objective To explore the value of tumor markers combined with clinical factors in predicting the sensitivity of neoadjuvant chemoradiotherapy(nCRT)in locally advanced rectal cancer.Methods Clinical data of 97 rectal cancer patients treated with nCRT from August 2013 to December 2020 were retrospectively collected,including gender,age,T/N staging,distance from anal margin,largest tumor diameter,tumor circumference ratio,concurrent chemotherapy regimen,operation interval,and serum levels of CEA,CA199,CA125 and CA724 before treatment.Grouping was conducted based on the tumor regression grade.Baseline data between different groups were compared by Pearson’s chi-squared test,and the variables with P<0.05 were introduced into the multivariate model for Logistic regression analysis.Results Multivariate analysis showed that pretreatment CEA≤5ng/ml and the largest tumor diameter≤5 cm were independent predictors of tumor regression and partial complete remission(pCR)in rectal cancer patients treated with nCRT(P<0.05).Conclusion Pretreatment serum CEA and tumor size have a significant value in predicting the sensitivity of neoadjuvant chemoradiotherapy for rectal cancer.

关 键 词：直肠癌 肿瘤标志物 新辅助放化疗 病理完全缓解 癌胚抗原 

分 类 号：R735.37[医药卫生—肿瘤]